Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Pediatric Transplantation

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1399-3046.2011.01560.xPMID 22004546
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Calcineurin Inhibitor Sparing in Paediatric Solid Organ Transplantation

  2012cited by this paper
• Use of sirolimus in liver transplant recipients with renal insufficiency: A systematic review and meta‐analysis

  2010cited by this paper
• The use of sirolimus as a rescue therapy in pediatric intestinal transplant recipients

  2010cited by this paper
• Multicentric outcome analysis of sirolimus‐based immunosuppression in 252 liver transplant recipients

  2010cited by this paper
• Inhibitors of the Mammalian Target of Rapamycin and Transplant Tolerance

  2009cited by this paper
• Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.

  2009cited by this paper
• Sirolimus in pediatric liver transplantation: a single-center experience.

  2009cited by this paper
• Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low‐dose calcineurin inhibitor regimens

  2008cited by this paper
• A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.

  2008cited by this paper
• Effects of rapamycin in liver transplantation.

  2008cited by this paper
• Conversion to sirolimus‐based immunosuppression in maintenance liver transplantation patients

  2007cited by this paper
• Calcineurin inhibitor-free protocols: risks and benefits.

  2007cited by this paper
• Immunosuppression in pediatric solid organ transplantation: Opportunities, risks, and management

  2006cited by this paper
• Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation: A Meta‐Analysis

  2006cited by this paper
• Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor‐induced nephrotoxicity

  2006cited by this paper
• A comparison of sirolimus vs. calcineurin inhibitor‐based immunosuppressive therapies in liver transplantation

  2006cited by this paper
• Sirolimus‐associated interstitial pneumonitis in solid organ transplant recipients

  2005cited by this paper
• Immunosuppression in liver transplantation: Beyond calcineurin inhibitors

  2005cited by this paper
• Replacing calcineurin inhibitors with mTOR inhibitors in children

  2005cited by this paper
• Nonnephrotoxic immunosuppression in patients after liver transplantation.

  2005cited by this paper
• Immunosuppression in pediatric liver and intestinal transplantation: a closer look at the arsenal.

  2005cited by this paper
• Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial.

  2004cited by this paper
• The Efficacy and Limitations of Sirolimus Conversion in Liver Transplant Patients Who Develop Renal Dysfunction on Calcineurin Inhibitors

  2004cited by this paper
• Effect of sirolimus on infection incidence in liver transplant recipients

  2004cited by this paper
• Short sirolimus half‐life in pediatric renal transplant recipients on a calcineurin inhibitor‐free protocol

  2004cited by this paper
• Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus

  2004cited by this paper
• Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma *

  2004cited by this paper
• Sirolimus and mycophenolate mofetil after liver transplantation

  2003cited by this paper
• Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications

  2003cited by this paper
• Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency.

  2003cited by this paper
• Rapamycin-based rescue therapy after chronic rejection in a pediatric liver transplant patient

  2003cited by this paper
• Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study

  2003cited by this paper
• Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine–based immunosuppressive regimen: incidence, risk factors, progression, and prognosis1

  2003cited by this paper
• Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus

  2003cited by this paper
• Sirolimus in pediatric transplant recipients.

  2003cited by this paper
• Rapamycin in children after liver transplantation.

  2003cited by this paper
• Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients.

  2003cited by this paper
• Ten years of sirolimus therapy in orthotopic liver transplant recipients.

  2003cited by this paper
• Delayed Wound Healing with Sirolimus after Liver Transplant

  2002cited by this paper
• The role of newer monoclonal antibodies in renal transplantation.

  2001cited by this paper
• Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus.

  2001cited by this paper
• mTOR inhibitors: An overview

  2001cited by this paper
• Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.

  2001cited by this paper
• Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation.

  2001cited by this paper
• Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients.

  2000cited by this paper
• Sirolimus: a potent new immunosuppressant for liver transplantation.

  1999cited by this paper
• Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

  1999cited by this paper
• Common medical diseases after liver transplantation.

  1998cited by this paper
• Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling.

  1998cited by this paper
• Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration

  1997cited by this paper
• Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

  1992cited by this paper

• Long Term Outcomes and Safety Profile of Sirolimus in Post Liver Transplant Children

  2025cites this paper
• Incidence and risk factors for chronic rejection in pediatric liver transplantation

  2024cites this paper
• Role of mTOR Inhibitors in Pediatric Liver Transplant Recipients: A Systematic Review

  2024cites this paper
• Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients

  2023cites this paper
• Types of Rejection

  2021cites this paper
• Menstrual disorders associated with sirolimus treatment

  2020cites this paper
• Listing for Transplantation; Postoperative Management and Long-Term Follow-Up

  2019cites this paper
• Experience in Africa

  2018cites this paper
• Pediatric Liver Transplantation: Our Experiences.

  2017cites this paper
• Early and Late Factors Impacting Patient and Graft Outcome in Pediatric Liver Transplantation: Summary of an ESPGHAN Monothematic Conference.

  2017cites this paper
• Induction and Standard Immunosuppression

  2017cites this paper
• Pediatric Liver Transplantation

  2016cites this paper
• Sirolimus Is a Successful Treatment for Recurrent Iron Deficiency Anaemia in Blue Rubber Bleb Naevus Syndrome

  2015cites this paper
• Anti-CD20 Monoclonal Antibody Therapy in Functional Bile Salt Export Pump Deficiency After Liver Transplantation.

  2015cites this paper
• Immunosuppression in Pediatric Kidney Transplant Patients

  2015cites this paper
• Chapter 92 – Special Considerations for Immunosuppression in Children

  2015cites this paper
• A review of the long-term outlook of children and young people post liver transplant

  2014cites this paper
• A child with unresectable biliary rhabdomyosarcoma: 48‐month disease‐free survival after liver transplantation

  2014cites this paper
• Central pontine myelinolysis following pediatric living donor liver transplantation: A case report and review of literature

  2014cites this paper
• Medical management of children after liver transplantation.

  2014cites this paper
• Design of bioartificial pancreas with functional micro/nano-based encapsulation of islets.

  2014cites this paper
• Management of Acute Rejection in Paediatric Liver Transplantation

  2013cites this paper
• Growing experience with mTOR inhibitors in pediatric solid organ transplantation

  2013cites this paper
• Use of sirolimus in pediatric heart transplant patients: A multi-institutional study from the Pediatric Heart Transplant Study Group.

  2013cites this paper
• Current World Literature

  2012cites this paper
• Conversion to sirolimus in pediatric renal transplant patients: A single‐center experience

  2012cites this paper
• to optimize

  2012cites this paper
• Lipid metabolism and oxidative stress in children after liver transplantation treated with sirolimus

  2012cites this paper
• The bile salt export pump (BSEP) in health and disease.

  2012cites this paper
• Everolimus in pediatric transplantation

  2012cites this paper
• Understanding immunosuppressive drugs for better management of infectious diseases in transplant recipients

  2012cites this paper
• Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures

  2012influential citation